The road to treating smoldering multiple myeloma Conference Paper

Authors: Korde, N.; Mailankody, S.; Landgren, O.
Title: The road to treating smoldering multiple myeloma
Conference Title: 2013 SOHO Annual Meeting
Abstract: The management of smoldering multiple myeloma (SMM) has been a challenge to clinicians, ever since the condition was first characterized in 1980. While the risk of progression to symptomatic myeloma is greater for SMM (10% per year) compared to MGUS (1% per year), several SMM patients remain asymptomatic for years without evidence of disease progression. Early clinical trials focusing on early treatment of SMM have been equivocal with no clear benefit. However, the last decade has seen a greater understanding of the pathogenesis of plasma cell disorders, including SMM, and development of better therapeutics. A recent randomized trial has provided evidence of clinical benefit with early treatment of high-risk SMM. In this review, we summarize issues related to the early treatment of SMM including risk stratification and possible outcomes with therapy initiation. In the context of reviewing recent clinical trial data supporting early treatment, we define challenges faced by clinicians and provide future directions to the road to treating SMM.
Keywords: lenalidomide; dexamethasone; risk; minimal residual disease; progression; plasma cells; long-term; disease; stage-i; undetermined significance mgus; monoclonal gammopathy; multiparameter flow-cytometry; high-risk smm; mgus; monoclonal protein
Journal Title Clinical Lymphoma, Myeloma and Leukemia
Volume: 14
Issue: Suppl.
Conference Dates: 2013 Sep 18-21
Conference Location: Houston, TX
ISBN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2014-09-01
Start Page: S59
End Page: S64
Language: English
ACCESSION: WOS:000346949500010
DOI: 10.1016/j.clml.2014.04.012
Notes: Article -- 3 -- Source: Wos
Altmetric Score
MSK Authors
  1. Carl Ola Landgren
    202 Landgren
  2. Neha Sanat Korde
    64 Korde